FGFR1 (8p11) Break
FGFR1 has been implicated in the tumorigenesis of haematological malignancies, where it is frequently involved in balanced chromosomal translocations, including cases of chronic myeloid leukaemia (BCR-FGFR1 fusion) and the 8p11 myeloproliferative syndrome/stem cell leukaemia–lymphoma syndrome, which is characterized by myeloid hyperplasia and non-Hodgkin’s lymphoma with chromosomal translocations fusing several genes, the most common being a fusion between ZNF198 and FGFR1.
FGFR1 (8p11) / SE 8 (D8Z1)
Amplification of the fibroblast growth factor receptor type 1 gene (FGFR1) has been observed in numerous cancer types including lung cancer (especially squamous cell carcinoma) and breast cancer. With the development of new therapeutic strategies, FGFR1 amplification could act as a valuable biomarker for R&D and provide an attractive tool for clinical stratification.
FGFR2 (10q26) and FGFR4 (5q35)
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signalling axis plays an important role in normal organ, vascular and skeletal development. It is also well documented that dysregulation of FGF-FGFR signalling via amplification, point mutation or translocations may have an important role in tumor development and progression. Alterations in FGFRs (i.e. overexpression, mutation, translocation, and truncation) are associated with a number of human cancers, including lung, myeloma, breast, gastric, colon, bladder, pancreatic, and hepatocellular carcinomas. A growing body of preclinical data demonstrates that inhibition of FGFR signalling can result in antiproliferative and/or pro-apoptic effects, thus confirming the validity of the FGFR/FGFR axis as a potential therapeutic target.
Brooks et al., 2012, Clin. Cancer Res. 18(7): 1855?62
Dutt et al. PLoS ONE 6: e2035.1
Kunii et al. Cancer Res. 2008; 68:2340-8.
Kwak et al, J Clin Oncol., 27(26):4247-53.
Liao et al. Cancer Res. 2013;73:5195-205.
Liang et al. Clin Cancer Res. 2013;19: 2572
Smedley et al, 1998, Hum Mol Genet. 7; 627-642.
Sohal et al, 2001, Genes Chrom. Cancer 32; 155-163.
Weiss et al., 2010, Sci. Transl. Med. 2(62): 62ra93
FGFR1 (8p11) / SE8 (D8Z1) - XL for BOND
FGFR1 (8p11) / SE8 (D8Z1) - XL for BOND (KBI-XL004) is intended for use in Fluorescence in situ Hybridization (FISH) on the BOND fully-automated staining systems.
The probe can be used to detect amplifications involving the FGFR1 gene. It has been validated on Non-Small Cell Lung Cancer (NSCLC) formalin-fixed, paraffin-embedded (FFPE) tissue sections.
FGFR1 (8p11) - XL for BOND (KBI-XL004R) probe is optimised to detect copy numbers of the FGFR1 gene at 8p11. The SE8 (D8Z1) - XL for BOND (KBI-XL004G) probe is optimised to detect copy numbers of the chromosome 8 centromere.
When combined, both probes are used to detect amplification of the FGFR1 gene at 8p11, using the centromeric probe as a control.
FGFR1 (8p11) – XL [ASR]
Introduction: The FGFR1 (8p11) - XL FISH ASR* probe is optimized to detect the FGFR1 gene region at 8p11.2.
Critical region (red): The FGFR1 (8p11) - XL FISH ASR* probe is direct-labeled with PlatinumBright 550.
Catalog Number: 08P004V550